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Abstract
ABCG2/BCRP is a membrane protein, involved in xenobiotic and endobiotic transport in
key pharmacological barriers and drug metabolizing organs, in the protection of stem cells,
and in multidrug resistance of cancer. Pharmacogenetic studies implicated the role of
ABCG2 in response to widely used medicines and anticancer agents, as well as in gout. Its
Q141K variant exhibits decreased functional expression thus increased drug accumulation
and decreased urate secretion. Still, there has been no reliable molecular model available
for this protein, as the published structures of other ABC transporters could not be properly
fitted to the ABCG2 topology and experimental data. The recently published high resolution
structure of a close homologue, the ABCG5-ABCG8 heterodimer, revealed a new ABC
transporter fold, unique for ABCG proteins. Here we present a structural model of the
ABCG2 homodimer based on this fold and detail the experimental results supporting this
model. In order to describe the effect of mutations on structure and dynamics, and charac-
terize substrate recognition and cholesterol regulation we performed molecular dynamics
simulations using full length ABCG2 protein embedded in a membrane bilayer and in silico
docking simulations. Our results show that in the Q141K variant the introduced positive
charge diminishes the interaction between the nucleotide binding and transmembrane
domains and the R482G variation alters the orientation of transmembrane helices. More-
over, the R482 position, which plays a role the substrate specificity of the transporter, is
located in one of the substrate binding pockets identified by the in silico docking calcula-
tions. In summary, the ABCG2 model and in silico simulations presented here may have
significant impact on understanding drug distribution and toxicity, as well as drug develop-
ment against cancer chemotherapy resistance or gout.
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Introduction
ATP Binding Cassette (ABC) transporters form one of the largest families of membrane pro-
teins and are involved in numerous physiological and pharmacological functions [1]. These
proteins are present from bacteria to human, and while in bacteria they may work both as
importers and exporters, in eukaryotes only the exporter function has been preserved. The
human ABC protein family includes 48 members, from which the members of the ABCB,
ABCC and ABCGproteins are key cellular exporters for xenobiotics and endobiotics [1, 2].
These promiscuous transporters provide the basis of protecting cells and tissue barriers against
hydrophobic toxic materials, regulate the ADME-Tox (Absorption, Distribution,Metabolism,
Excretion, and Toxicity) properties of numerous clinically applied drugs, and are involved in
cancer chemotherapy resistance.
In spite of the huge amount of data about the mechanism of action, cellular localization,
and pharmacogenetically important polymorphisms and mutations of the human ABC drug
transporters, the structural features of these large membrane proteins are hardly known [3–5].
There are several crystallization-basedexperimental data for bacterial importers and exporters,
while practically only one single set of such data are available for the mammalian (mouse)
ABCB1 drug transporter [6]. Still, numerous homologymodels have been built for other
human ABC drug transporters, either based on this ABCB1, or the bacterial ABC transporter
structures [7–9].
The ABCG2 protein is a multifunctional human membrane transporter–it is expressed at a
high level in the gut, in the blood-brain and the feto-maternal barriers, and its function is espe-
cially relevant in stem cell protection [10–12]. Overexpression of ABCG2 has been shown to
cause cancer multidrug resistance [13–15], while a reduced expression or function is an estab-
lished cause of hyperuricemia and gout [16–18]. Still, it has been especially challenging to
model the atomic level structure of ABCG2, as the nucleotide binding domain (NBD) and the
transmembrane domain (TMD) arrangements are in an inverse order than in the ABCB or
ABCC families, and membrane topology studies indicated a completely different transmem-
brane helix arrangement for this protein.
Very recently the crystal structure of the ABCG5-ABCG8heterodimermembrane protein,
the key human transporter for cholesterol, has been published [19]. These proteins, as mem-
bers of the human ABCG subfamily, show close homology to the homodimericABCG2 trans-
porter. Since ABCG2 has major medical importance, here we provide a homologymodel for
this protein, based on the ABCG5-ABCG8structure.We also provide explanations for the
polymorphism and mutations with experimental or clinical relevance [20–23]. Moreover, by
utilizingmolecular dynamics simulations and in silico docking calculations, we describe the
potential drug binding and transport regions, as well as the residues responsible for the special
cholesterol sensitivity of this promiscuous drug transporter. Clearly, these structural data may
provide important clues to decipher the effects of the ABCG2 variants, design drugs to rescue
their expression, or drugs to modulate their function in stem cell development, protection of
the fetus or cancer drug resistance.
Methods
Homology modeling
Sequence alignment of ABCG2_HUMAN,ABCG5_HUMAN, and ABCG8_HUMAN(Uni-
Prot) was generated using ClustalW [24]. Modeller 9.12 was employed to generate the homol-
ogymodels [25]. Cysteines 592 and 608 were constrained to form intramolecular disulfide
bonds, while cysteines at position 603 were forced to participate in an intermolecular S-S
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bridge. One hundred models were prepared and the best model was selected by Modeller’s
DOPE score. Since the extracellular loops contained knots, the loops betweenC592 and C608
were refined also by Modeller, employing the same approach: 100 loopmodels were created
and evaluated by DOPE score.
Mutant constructs could be generated simply by PyMOL (The PyMOLMolecular Graphics
System, Version 1.7 Schrödinger, LLC.), since either the side chain of the new residue was
small or it was on the protein surface. PyMOL was used to generate all the molecular graphics.
Sequence alignments, structuralmodels, and additional information on molecular dynamics
and in silico docking (see below) can be downloaded from http://abcg.hegelab.org to facilitate
further studies.
Molecular Dynamics (MD) simulations
The structuralmodels were oriented along the membrane normal based on the ABC-
G5-ABCG8 orientation in the OPM (Orientations of Proteins in Membranes) database [26].
MD simulations were performed using GROMACS 5.1 with CHARMM36 force field [27, 28].
The input files for energyminimization, several equilibration steps (NVT, NPT), and produc-
tion run were generated via the CHARMM-GUI web interface [29, 30]. The following options
were selected: terminal residues were patched by ACE (acetylated N-terminus) and CT3 (N-
methylamide C-terminus), the extracellular cysteines were set to form disulfide bridges;
homogenous POPC (1-palmitoyl-2-oleoyl-sn-glycero-3-phosphocholine) lipid bilayer were
selectedwith default parameters and 150 mMNaCl was inserted; grid information for PME
(Particle-Mesh Ewald) electrostatics was generated automatically, NPγT ensemble was selected
with constant number of particles (N), pressure (P) of bar, surface tension zero (γ), and tem-
perature of 310 K. All the wild type and mutant structures were energyminimized in the first
step using the steepest descent integrator (maximum number to integrate: 5,000 or converged
when force is<1,000 kJ/mol/nm). From each energyminimized structure we forked six paral-
lel simulations containing consecutive sets of equilibration steps, when decreasing force con-
stants (from 4,000 to 50 kJ/mol/nm2) in these steps were applied for protein and lipids.
Production runs were performedwithout restraints. Berendsen thermostat and barostat were
used in the equilibration steps, while Nose-Hoover thermostat and Parrinello-Rahman barostat
with semiisotropic coupling were employed in the production run. Time constants were 1 ps
and 5 ps for the thermostats and barostats, respectively. Electrostatic interactions were calcu-
lated using the fast smooth PME algorithm and LINCS algorithmwas used to constrain bonds.
Simulations were carried out in constant particle number, pressure, and temperature ensem-
bles with a time step of 2 fs. In summary, all the parameters provided by the CHARMM-GUI
interface were unchanged and used except the simulation time in the production step, that was
set to 50 ns. Thus six parallel runs resulted in 300 ns total simulation time for each constructs
includingWT, Q141K, R486G, and Y413S. Simulations were executed on a GPU cluster of the
NIIF National Information InfrastructureDevelopment Institute (http://www.niif.hu/en). Sim-
ulations were analyzed by the MDAnalysis Python package [31] and in-house Python scripts
on our local small HPC cluster.
In silico docking
Molecules are listed in the Supplementary material (S6 Fig). The OpenBabel package and
MGLTools scripts were used to convert betweenmolecule file formats and to prepare the mole-
cules for docking using AutoDock Vina [32, 33], respectively. The six conformations of
ABCG2wild type were taken from the last frame of the equilibrium simulations and prepared
for docking using MGLTools (Gasteiger charges were added). The docking space was defined
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by a box around the whole transmembrane domain including also some parts of the NBD and
the extracellular loops (S5 Fig). Because of the large volume of the box, exhaustiveness was set
to 128 instead of the default value 8 and the number of required poses in the output (num_-
modes) was set to 20. Analysis was performed by PyMOL and in-house Python scripts.
Results and Discussion
Homology modeling based on the new ABC transporter fold provides a
plausible and stable ABCG2 model
In contrast to previous ABC transporter structures, the recent ABCG5-ABCG8high resolution
structure provides an excellent template for modeling ABCG2 [19]. ABCG2 exhibits 27% and
26% identities and 48% and 44% similarities when compared to ABCG5 and ABCG8, respec-
tively. Although these values seem to be low for general homologymodeling, for longer
sequences (> 100 a.a.) and especially for membrane ABC proteins they are sufficient (seeMod-
eller’s tutorial and [34]). Even in a worse scenario, when the N- and C-terminal halves of
CFTR/ABCC7(Cystic Fibrosis Transmembrane Conductance Regulator) exhibit only 18% and
21% identities compared to the Staphylococcus aureus Sav1866 protein, using this distantly
related protein as a template resulted in a high quality CFTR homologymodel that could be
confirmed by experiments [9]. Bacterial homolog basedMDR1 (P-gp) models also have been
generated and widely used to guide experimental and computational studies [35–37]. Although
the ABCG5-ABCG8template is a heterodimer, the structural differences between the two
halves are subtle (S1 Fig). Based on these considerations, we generated a homologymodel of
ABCG2 based on the ABCG5-ABCG8structure (Fig 1) employing the sequence alignment
shown in S2 Fig. Although the alignment generation was relatively straightforward, some parts
of the ABCG2 protein were not modeled, either because they are mobile and thus invisible in
the template structure, or their sequence and length differ from the corresponding regions in
the template (e.g. the loop between the β1 and β2 strands of NBD and the linker region between
the NBD and TMD; see details below and S2 Fig).
Large deviations from the starting structure are expected even in short (<20 ns) MD simula-
tions when the initial structure is wrong or inaccurate [6, 38–40]. Therefore we performed
molecular dynamics simulations employing the ABCG2 homodimer embedded in a membrane
bilayer to confirm the stability of the homologymodel. RMSD values of frames compared to
the initial structure indicated the stability of our model (S3 Fig). Although it would be interest-
ing to perform experiments testing specific aspects of the ABCG2 structuralmodel employing
devisedmutations, as in the case of the CFTR homologymodel [9], the ABCG2 transporter is
highly sensitive to mutations and its cysteine-less form cannot be functionally expressed [41].
However, there are several experimental observations, which we discuss in the next section,
supporting our model.
The nucleotide binding domains (NBDs) are the most conserved regions in all ABC proteins
from bacteria to human, and consist of a RecA-like core domain present in all P-loop ATPases,
and an α-subdomain characteristic exclusively for ABC proteins [4, 5, 42]. TheWalker A and
Bmotives responsible for ATP binding are located in the core domain, while the ABC signature
sequence (LSGGQ), which provides the catalytic base toward the γ-phosphate, is situated in
the α-subdomain (S2 Fig). Since ATP binds to theWalker A sequence in one NBD, and the sig-
nature sequence is provided from the other NBD, for ATP hydrolysis an intimate interaction
of the two NBDs is required [4, 5, 42]. It is also important to mention that the ABCG5-ABCG8
heterodimer exhibits a functional asymmetry in the NBDs, as ABCG5 possesses a degenerate
signature sequence thus unable to cleave ATP. In the ABCG2 dimer both ATP sites are active.
The ABCG5-ABCG8structure does not contain bound ATP, thus the NBDs were separated
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Fig 1. The general structural properties of the ABCG2 homology model. The two monomers are colored by different light green
colors. The most important parts, providing the interface between the TMD and NBD are the coupling helix (light blue) and the connecting
helix (dark green). The functionally important R482 is colored ruby. The site of the most frequent polymorphism, Q141 is deep purple. The
location of important mutations affecting biogenesis and function are labeled by dark green (R383) and orange (K86), respectively.
Residues, which are probably significant in cholesterol modulation, are blue (Y413) and magenta (a.a. 555–558). Gray dots represent the
boundaries of the hydrophobic region of the bilayer, defined by the OPM webserver. Insert: ABCG2 (green) and mouse ABCB1/Pgp
(blue, PDBID: 4M1M) are overlaid. The mouse ABCB1 NBD is much further from the membrane bilayer and the distance between the
NBDs of ABCB1 and ABCG2 (the Cα atoms of the Walker A Lys residues; K433 and K86, respectively) is 26 Å.
doi:10.1371/journal.pone.0164426.g001
Structural Model of ABCG2
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[19], and so are they now in the ABCG2 structure presented. However, in contrast to that in
the mouseMDR1 structure [6], the NBDs are not fully separated, and a connection is provided
by helices located at the C-terminus of NBDs. Till now this conformation could have been
observedonly in lower eukaryotes [43, 44].
In the ABCG type proteins the loop between the first and second β-strands of the core
domain are longer than in most ABC transporters (approx. 20 a.a. in ABCG2, and 20 and 40 in
ABCG5 and ABCG8, respectively; S2 Fig). This loop is invisible in both the ABCG5 and
ABCG8 crystal structures, thus most likely highly mobile. The only loop, which has been
described at the same location, is the so called “regulatory insertion” in the CFTR protein [45].
However, this region of the NBD does not play any role in phosphorylation or nucleotide
dependent regulation of CFTR function.When this “regulatory insertion” was deleted in
CFTR, the thermostability of this channel was increased significantly, but no physiological
function for this segment could be identified [46]. Until now the existence of this long loop in
ABCGproteins has not been known because of the lower sequence conservation of the
β1-strand and its function is unknown. Since it includes the short A-loop motif [47], one of its
functions supposed to be ATP stabilization. However, its length suggests additional roles, and
we propose that it may serve as a filter at the entry to the substrate binding cavity (see below),
and contribute to the first step of allosteric communication of signaling drug biding to the ATP
binding site.
The transmembrane domain in the ABCGproteins exhibits a completely new ABC trans-
porter fold. The intracellular loops are shorter compared to known ABC exporter structures,
that results in a small distance of the NBDs from the inner layer of the membrane (Fig 1 insert).
In this respect the structures of the ABCGproteins resemble the bacterial importers, but their
transmembrane fold is completely different. In addition, no intracellular loops do cross over
from one TMD to the opposite NBD, as observed in previous ABC exporter structures [9, 48].
Moreover, the arrangement of the short, so called coupling helices, which are located at the
NBD/TMD interface and couple the motions resulting from ATP binding and hydrolysis in
the NBDs to conformational changes in the TMD, are completely different from those found
in the ABCB or ABCC type proteins. One of the intracellular loops betweenTH4 and TH5
(ICL2), in contrast to other ABC exporter folds, is so short that it does not leave the bilayer,
thus does not reach the NBD and cannot function as a coupling helix, providing a molecular
coupling. The only potential coupling helix in ICL1 (a.a. 452–461), located betweenTH2 and
TH3, binds to the NBDs similarly to that observed in other ABC structures [9, 42] (Fig 1), but
in a slightly different conformation. Interestingly, while there are bacterial importers that pos-
sess only one coupling helix in one half of the transporter, ABCGs still possess more interac-
tions between the TMDs and NBDs. An amphipathic helix (a.a. 373–390; Figs 1 and 2 and S2
and S3 Figs) similar to a coupling helix provides additional interactions and is located in the
linker region directly before TH1. The coupling helix like conformation of this region, which is
named “connecting helix” [19] and forms an alpha helix perpendicular to the TM helices, is
established by its amphipathic nature. However, this connecting helix does not penetrate as
deeply into the NBDs as the coupling helices in Type I ABC exporters. In addition, this con-
necting helix exhibits similar structural and functional roles as those coupling helices which
cross over from one TMD to the opposite NBD in the other half of the molecule, in type I ABC
exporter structures.
An interesting and ABCG specific region of the new fold is an extracellular loop between
TH5 and TH6 (ECL3; a.a. 552–621) with a special conformation. The residues located
between 562 and 586 form two consecutive helices, exhibiting a V-shape, immersed partially
into the bilayer (S2 and S4 Figs). This re-entering into the membrane resembles the P-loop of
ion channels, and thus we propose to name it a G-loop. The extracellular loop following the
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G-loop in the ABCG proteins is not highly conserved and is slightly different in its length.
ABCG8 does not possess any cysteines in this region, while the two cysteines in ABCG5G-
loop are at similar positions as C592 and C608 in the ABCG2. It has been experimentally
documented that these cysteines form an intramolecular disulfide bond in the ABCG2 pro-
tein [49], while this covalent bond is not observable in the ABCG5-ABCG8structure, because
purification and crystallizationwere done under reducing conditions. In addition, in ABCG2
it has been shown that the two C603 residues in the two halves of ABCG2 form an intermo-
lecular disulfide bond [49, 50]. The experimentally verifiedN-glycosylation site in ABCG2 at
position N596 [51] in our ABCG2model is found in the flexible extracellular loop 3 and
accessible for glycosylation.
As described above, the ABCG family members have entirely different conformational
arrangements in the transmembrane helices and connecting regions than the other known
ABC exporters. Therefore it is not surprising that until now the structure of ABCG-like pro-
teins could not have been properly predicted—all attempts were based on the presumption
that the NBDs are located far from the bilayer and are connected to the TMD with long intra-
cellular loops [8, 52–54]. In addition, experimental findings that supported the long ABC
fold in ABCG type proteins may raise serious concerns (see Fig 1 insert). Moreover, studies
which attempted to determine the ABCG2 transmembrane topology by HA-insertion experi-
ments, seriously failed [54, 55]. This was most likely caused by a misinterpretation of the
expression and function of the mutant variants, biased by the misconception of presuming
long intracellular loops in TMDs. In contrast, the in silico prediction of the ABCG2mem-
brane topology performedmuch better, and resulted in TM helix boundaries similar to those
deducted from the ABCG5-ABCG8crystal structure and the present ABCG2model (S1
Table) [56, 57].
Fig 2. The Q141K variant interferes with the coupling between the NBD and the connecting helix. The side chain of F142, which is at
a homologous position as the CFTR F508 (S2 Fig), is clamped by the positively charged K382 and R383. The positive charge of 141K
destabilizes this interaction by repulsion with K382, as shown by molecular dynamics simulations (S5 Fig).
doi:10.1371/journal.pone.0164426.g002
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The new model contributes to the understanding of the effects of
ABCG2 variations
Structuralmodels, even homologymodels with their limitations, are important tools to assess
the effects of both natural variations, and mutations generated for structure/functionstudies. A
prominent example in the field is the CFTR homologymodel based on the Sav1866 structure
[9]. While these proteins share very low homology in the TMDs, major structural features
could have been confirmed by experiments and the model still serves as a fundamental basis
from basic studies to drug development. Below we detail the experimentally examined specific
residues and regions in the ABCG2 protein, in order to assess the suitability of the newmodel
to understand their effects on ABCG2 structure and function.
The K86Mmutation, within theWalker A ATP binding motif has been used in numerous
studies to generate a non-functional ABCG2 transporter, lacking both ATPase and transport
activities [58]. Similarly to other ABC transporters, the NBD/NBD domain interface is highly
sensitive for mutations, irrespectively whether the actual residue plays a role in the catalysis.
The E211Qmutation, causing loss of function, is localized in this region [59].
Two major polymorphic variants of ABCG2 are V12M and Q141K [22]. V12M, present in
5–10% frequency in human populations, has been shown not to have a measurable effect on
the processing or function of the protein. The lack of effect can be explained by the position of
this variation located in the short and flexible N-terminal region of the protein (a.a. 1–30). Tag-
ging experiments are also in line with the spatial arrangement of the N-terminus: either a 6–10
histidine tag, or even a large GFP tag, attached to this end, is well tolerated in ABCG2 process-
ing and function [60].
Q141K, present in about 15–30 percent of people in various ethnic groups, causes a signifi-
cant reduction in intracellular trafficking and plasma membrane localization of ABCG2 [20,
21]. Due to the reduced expression at the site of action, this variant contributes to the develop-
ment of gout and enhances the side effects and toxicity of various drugs [16–18, 61–63]. Inter-
estingly, Q141 within the NBD is located next to F142, homologous to the CFTR F508 (Fig 2)
[64], in a helix interacting with the amphipathic “connecting helix”. This site is analogous to
the crossed-over coupling helix of cytoplasmic loop 3 in CFTR, and may similarly have a role
in stabilizing the NBD/TMD interface [9, 65].
The side chain of Q141 is directed towards N158, thus the substitution of glutamine by the
larger lysine with a positive charge, may displace the α-helix of N158. This helix is on the exter-
nal side of the NBD, thus expected to cause only a minor effect on the transporter function.
Molecular dynamics simulations indicate that these helices do not move differently in the
Q141Kmutant as compared to the wild type protein. On the other hand, the distances between
the connecting helix and the helix of Q141 and F142 exhibit differences in dynamics (S5 Fig).
The interaction at this NBD/TMD interface is stabilized by a special arrangement of three
amino acids (Fig 2). The side chains of K382 and R383 in the connecting helix form a V-shape,
and clamp the residue F142 located in the NBD. In the Q141K variant the positive charge inter-
feres with K382, the interaction of the two helices is destabilized, and exhibits an increased
probability of divergence for the two interfacing helices. In the light of this observation, the cru-
cial role of R383 in stabilizing the NBD/TMD interface is highlighted and the deleterious
impact of R383 mutations on ABCG2 biogenesis is interpretable [66].
Experimental studies have shown that while the Q141K variant causes only a partial
impairment in ABCG2 processing, the ΔF142 mutant has a more severe effect than the ΔF508
mutation in the CFTR protein [64]. Misprocessing of ΔF142 ABCG2 cannot be rescued either
by temperature or correctors, most likely because in the case of ABCG2 every single mutation
behaves as a double mutation in the homodimer transporter. The molecularmodeling and
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experimental studies may significantly contribute to explore the already available CFTR correc-
tors to rescue the ABCG2Q141K variant, e.g. in the therapy of gout [65]. Still, the local molec-
ular environment is dissimilar to that observed in CFTR, namely the connecting helix is less
embedded into the NBD, and the interacting residues are not hydrophobic in ABCG2, thus
any CFTR corrector compounds tested for rescuing ABCG2Q141K [65] should be tuned for
the structure of ABCG2. In addition, CFTR F508 resides in a loop following a helix, while
ABCG2 F142 is located in an α-helix.
In ABCG2 a historically and functionally important residue is the arginine in position 482
[58, 67]. In the first ABCG2 cloning experiments drug resistant cell lines expressed the R482G
variant, which has a different substrate and inhibitor specificity and apparently a higher drug
transport turnover that the wild-type protein. Still, this variant has not been found in vivo,
probably because it cannot transport negatively charged substrates, including uric acid or con-
jugated hydrophobic drugs [23]. In the new ABCG2model R482 resides in TH3, very close
(2 a.a.) to a kink generated by P480. This proline, and most likely also the kink, are conserved
in ABCGs (S2 Fig). As discussed below, the role of R482 in the substrate handling of ABCG2 is
strongly supported by the current model.
The short cytoplasmic C terminus of the ABCG2 protein has been shown to be very sensi-
tive to any experimentalmodification or tagging. This is well explained by the localization of
these amino acids, facing the inner “cavity” of the dimer in very close proximity to the coupling
helix and most probably interacting with it.
Docking calculations reveal drug binding sites along a potential
transport pathway
In silico docking studies on multidrug transporters have not been a great success. Since it is
challenging to handle the plasticity of a binding site capable of interacting with chemically dif-
ferent compounds and in silico docking to a homologymodel raises the concern regarding side
chain orientations, we performed docking to several conformations generated by the equilibra-
tion steps of the molecular dynamics simulations. This process also provided a more physiolog-
ical orientation of the side chains in the lipid regions, as the protein in the simulations was
embedded in a lipid bilayer. These conformations possess similar backbones, since the protein
is position-restrained during the main part of the equilibration process. To these conforma-
tions we docked various ABCG2 substrates including sulfasalazine,methotrexate, rhodamine
123, flavopiridol, and also molecules that do not interact with ABCG2 such as verapamil and
calcein (S6–S8 Figs) [2, 12, 15], employing AutoDock Vina [33].
Interestingly, the conformations exhibited various characteristic locations for substrates
(Fig 3): some of the conformations indicated potential binding sites around the entry pore
from the cytosol (Sites 1 and 2), others delineated the entry to the interface of the two trans-
membrane domains (Site 3), and some exhibited a partially extracellular location (Site 4). Site 1
is situated below the connector and coupling helix, and above the loop connecting the core and
α-helical subdomains of NBD. Site 2 is a more defined binding pocket, intercalated between
TH1 and TH4, which also includes the R482 and the P480 kink. Site 3 is located between the
two monomeric subunits, surrounded by TH2 and TH5, provided by both monomers. Amino
acids of Site 4 are part of the tip of the TH helices and extracellular loops. Binding to this site
was a rare event, indicating that the conformations of this region captured in the MD simula-
tions do not form a real binding pocket, as expected for an off-site.
Interestingly, while both substrates and non-substrates can bind to Site 1, the entry into Site
2 of non-substrates is limited (e.g. for verapamil or calcein; S7 and S8 Figs and S2 Table). Thus
substrate selection, e.g. differentiation of toxic molecules from natural metabolites, may happen
Structural Model of ABCG2
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at this site. This proposal is also strengthened by the fact that R482, which exhibits a strong
effect on substrate selectivity, is part of Site 2. It is also important to note that mutations of
T402 and P485 in this pocket (S8 Fig) have been reported to reduce the transport of many sub-
strates [8, 68], further supporting the existence of Site 2. It seems that all the molecules exam-
ined can bind into the central pocket (Site 3), which might be the entry point into the pathway
between the two TMDs. In addition, for substrates, binding regions overlapping between Sites
2 and 3 also can be observed, delineating a potential transition spot from Site 2 to Site 3. Site 1
and Site 2 are present at both monomers, although their presence is not so pronounced in one
of the monomers in our conformations because of the inherent asymmetry of the ABC-
G5-ABCG8 template. Site 3 is located between the two monomers, as a part of the main trans-
location path, and substrates can enter this pocket from Site 2 of either monomer in an
alternating fashion (Fig 3). The central large cavity in the apo structures of ABCG5-ABCG8
and ABCG2 dimers exposes both hydrophobic and hydrophilic residues, and their pattern also
may play a role in discriminating substrates and non-substrates. In addition, the loop between
the β1 and β2 strands of NBDs may also limit the access to the entry sites and participate in
substrate selection.
Fig 3. In silico docking shows binding sites along a potential substrate pathway. Substrates and non-substrates were docked to six ABCG2
conformations. Both types of molecules could dock at Site 1 (blue), while only the binding of substrates could be observed at Site 2 (red). The central Site 3
(yellow) resides between the two monomers. A potential off-site at the extracellular part is also revealed (Site 4, magenta). Here, docking poses of
sulfasalazine are shown in the case of two ABCG2 conformations (two out of the last frames of the six equilibrations are shown).
doi:10.1371/journal.pone.0164426.g003
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In silico modeling facilitates to uncover the atomic details of cholesterol
dependence of ABCG2 function
Membrane cholesterol is a major modulator of ABCG2 function, as documented by several
experimental studies [69–71]. In fact, purifiedABCG2 is practically non-functional without
the addition of cholesterol to the reconstituting lipids [60]. Experimental studies indicated that
the R482Gmutation also influences the cholesterol sensitivity of ABCG2, that is less choles-
terol is required for full transport function [69]. Since this amino acid is in the hydrophobic
region, it is questionable how could cholesterol interact with this residue. Most probably R482
alters the conformation and dynamics of TM helices, resulting in altered cholesterol sensitivity
and substrate specificity (see above).
In order to test this hypothesis we executedMD simulations using the R482Gmutant
embedded in a lipid bilayer, and compared the conformation of the TM helices close to this res-
idue, located in TH3. Even in the case of a limited accessible time scale, large conformational
changes could be observed (Fig 4 and S9 Fig). In the absence of the large R482 side chain, TH3
moved closer to TH4 and at the same time drifting away from TH1. These conformational
changes caused by R482 substitution indeed have a significant effect on regions, which have
been proposed as cholesterol binding sites (e.g. TH1), and also on drug binding site 2, thus
Fig 4. Structural effects of the R482 variations. The R482G mutation is able to alter the positioning of TM
helices and the conformation of the P480 kink. Two structures were taken from the end of two simulations, which
exhibited the largest changes, to decipher and demonstrate the effect of R482. The distances between Cα of R482
(TH3) and that of Q398 (TH1), S441 (TH2), and A517 (TH4) were measured throughout the simulation trajectory,
and in the last frame exhibited the following values: distances of A, B, and C in WT are 8.4 Å, 7.2 Å, and 7.4 Å,
while in the R482G variant are 15.1 Å, 8.1 Å, and 4.9 Å, respectively. The right panels contain both the WT and
R482 structures in cylindrical representation. Arrows are placed at spots, which exhibit the most pronounced
differences between the two constructs, and point from the wild type to the mutant conformation. TH1-6 are
colored by red, green, blue, orange, magenta, and yellow, respectively.
doi:10.1371/journal.pone.0164426.g004
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provide suitable explanations for both altered cholesterol sensitivity and substrate specificity of
this variant.
Two recent publications explored the putative cholesterol binding sites in ABCG2 by muta-
genesis. Gal et al. [72] investigated the effects of mutations of the key tyrosine residues in the
putative cholesterol recognition amino acid consensus (CRAC) motives, located in ABCG2 at
positions Y413, Y459, Y469, Y570 and Y645 (S4 Fig). The Y459S mutation prevented protein
expression, the Y469S and Y645S mutants lost their transport and ATPase activities, while the
only significant effect on cholesterol modulation of ABCG2 functionwas caused by the Y413S
mutation. In the second related study [73] a leucine based potential cholesterol binding motif
(a.a. 555–558) was found to play a significant role in the cholesterol dependence of ABCG2.
The structuralmodel of ABCG2presented here revealed that Y459 is located in the coupling
helix and its mutation understandably caused a major detrimental effect. The Y413S CRAC
motif mutation, that significantly altered the cholesterol sensitivity of ABCG2without major
functional effects, is located in the extracellular tip of TH1, in the area of the external lipid head
groups, as supported by molecular dynamics simulations, performedwith the transporter
embedded in a POPC lipid bilayer (Fig 5). Most interestingly, the leucine basedmotif (a.a. 555–
558), affecting the cholesterol sensitivity of ABCG2 is located just before the G-loop, in the outer,
charged leaflet of the bilayer, close and in a potentially interacting position with the Y413 in the
CRACmotif in the opposite monomer. These observations strongly suggest that the cholesterol
binding site is located in this region. It may be supposed that an intermolecular interaction
betweenY413, L555, and V556 provide a specific, potentially dynamic conformation for the TM
Fig 5. The structural background of cholesterol regulation. The last frame of a 50 ns long MD simulation with ABCG2
embedded in a POPC bilayer shows that the CRAC motif, containing Y413, is located in the charged area of POPC head
groups (orange), as a rational location for cholesterol biding. Also, the leucine based cholesterol binding motif (magenta)
is situated in this layer. Right panel: zoomed area reveals a close contact between the CRAC and the leucine based
motives (e.g. Y413 and V556 are closer than 5 Å) and may provide a cholesterol binding site (black circle). Gray: POPC
hydrophobic tails; orange: charged head groups of lipids.
doi:10.1371/journal.pone.0164426.g005
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helices in cholesterol binding. The special localization of these twomotives also suggests that cho-
lesterol may contribute to the stabilization of the dimer in a specific conformation.
Since the Y413S mutation may affect cholesterol sensitivity of ABCG2 allosterically, and
experimental studies to identify the direct binding of such a hydrophobic molecule are
extremely difficult, we performedMD simulations with the Y413S mutant construct.We could
not observe any significant changes in the dynamics in TH1 (S10 Fig), that also suggests that
the altered cholesterol sensitivity observed in this mutant is caused directly by this functional
CRACmotif.
Concluding remarks
The ABCG5-ABCG8based homologymodel of ABCG2 presented here is capable to shed light
on the effects of mutations, substrate handling, and also on the regulation of this transporter.
The altered dynamics of the R482G variant provides explanation for both altered substrate
specificity via affecting the drug binding pocket (Site 2), and to the altered cholesterol regula-
tion through allosteric communication via TH1 to CRACmotif (Y413). As this ABC-
G5-ABCG8 based homologymodel behaved unexpectedlywell in the simple computational
approaches we applied, without any sophisticated additional methods,most likely the ABC-
G5-ABCG8 structure is a physiologically relevant conformation. Importantly, this conforma-
tion exhibits only slightly separated NBDs without bound ATP and exposes drug binding sites
without widely separated TM helices at the cytoplasmicmembrane leaflet.
The existence of the observedbinding sites in the six conformations used in in silico docking
calculations leads to important implications. Namely, subtle conformational changes (the max-
imum RMSD between the six equilibrated structures is 1.3 Å) are sufficient to provide binding
sites at different regions of the protein, without the need of large movements or largely sepa-
rated NBDs. Most likely the alternating access mechanism, which has been proposed to involve
a drug binding conformation with widely separated intracellular parts and a release conforma-
tion widely opened to the extracellular space, is realized differently in the case of ABCG export-
ers. Based on the ABCG5-ABCG8structure and our results with the ABCG2model we
hypothesize that the conformational changes needed for transport involve subtle repositioning
and rotation of the transmembrane helices and these play a more pronounced role in the trans-
port than have thought before. Supported by our results we are convinced that the ABCG2
model presented here may pave the road for drug design and understandingmultidrug recog-
nition and transport.
Supporting Information
S1 Fig. Structural alignment of ABCG5 and ABCG8.Chain A (ABCG5, green) and chain B
(ABCG8, blue) from the heterodimer structure (PDBID: 5DO7) are highly similar (RMSD 2.1
Å) except in the linker region.
(TIF)
S2 Fig. Sequence alignments of ABCG subfamilymembers and CFTRNBD1. (A) Sequences
of the ABCGproteins downloaded from the UniProt database (ABCG1_HUMAN,ABC-
G2_HUMAN, ABCG4_HUMAN,ABCG5_HUMAN, and ABCG8_HUMAN)were aligned
employing ClustalW. ABCG2N-terminus including NBD (a.a. 1–300) and CFTRNBD1
(CFTR_HUMAN, a.a. 381–645) were aligned separately, since CFTRNBD1 sequence has
unique features, which result in suboptimal alignments even for demonstration purposes when
aligned together with all ABCGproteins. The CFTRNBD1 was mergedmanually from this
pairwise alignment into the multiple alignment. Since the CFTR transmembrane domain is a
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Type I exporter fold and not similar in either length or sequence to ABCGproteins, this TMD
is not included in the alignment. Important regions and amino acids positions are labeled
above the alignment and their numbering refers to ABCG2 positions. Since ABCG2 exhibit
somewhat higher similarity to ABCG1 and ABCG4, the alignment of ABCG2 to ABCG5 and
ABCG8 is not optimal at a fewminor positions (labeled with red arrowheads). (B)We also
generated pairwise alignments of the ABCG2 to the templates that was used for homology
modeling and contains concatenated dimers of ABCG2 (labeled as ABCG22) and ABC-
G5-ABCG8 (labeled as ABCG58). The loop between the NBD β1 and β2 strands are highly dif-
ferent in length resulting in highly misaligned sequences of this region, thus the β1 sequence of
ABCG8was manually aligned to the β1 sequence of ABCG2. The linker region was not mod-
eled because of low sequence similarities and its flexiblemissing parts in ABCG5-ABCG8.The
ABCG2 sequence exhibits sufficiently high similarity to the templates (identity ~25% and simi-
larity over 40%) that allows generating high quality homologymodels in the case of these ABC
transmembrane proteins (Modeller tutorial and [34]). The alignment was drawn using Jalview,
colored according to the ClustalX color scheme, and can be downloaded from http://abcg.
hegelab.org. The monomer’s boundaries are indicated by red arrowheads, while locations of
breaks in the structure are indicated by black arrowheads.
(TIF)
S3 Fig. MD simulations show the stability of the homologymodel and the mutant con-
structs.We performed six parallel 50 ns long MD simulations with every constructs embedded
in a lipid bilayer. All of them exhibited a stable structure, with sufficiently stabilized RMSD and
energy values that can be considered acceptable for such a large and stable system. Major dis-
tortions, which were published for MD simulations with crystal structures of other ABC trans-
porters, could not be observed in the case of our structuralmodel [38,39].
(TIFF)
S4 Fig. Important regions and amino acid locations are highlightedon the ABCG2model.
Cysteines (red) were constrained to form intramolecular (C592-C608) or intermolecular
(C603-C603) disulfide bonds. The glycosylation site N596 (black) resides in a mobile loop indi-
cated by molecular dynamics simulations. Amino acids between 562 and 586 form two conse-
cutive helices, which are immersed partially into the bilayer and resembles to the P-loop of ion
channels, thus we propose to name it as a G-loop (yellow). CRACmotives are labeled blue and
the coupling helix light blue. The tyrosines in the potential CRAC motifs (Y413, Y459, Y469,
Y570 and Y645, see text) are colored blue. R482 and P480, which proline creates a kink in the
helix, are colored ruby and pale green, respectively.
(TIFF)
S5 Fig. The Q141Kmutation may cause repulsion with K382 and weaken the NBD/TMD
interface.Although the Q141 side chain points towards N158 (Fig 2), the Q141Kmutations
does not exhibit a pronounced effect of the distances of the helices, in which these amino acids
are located (not shown). However, the positively charged 141K interferes with the side chain of
K382, which restrains F142 with R383 (see Fig 2). This is revealed by MD simulations showing
increased distances and higher variability of distances between the Cα atoms of restudies 141
and 382 in the Q141K variant, as compared to the wild type protein. All the 5,000 frames were
analyzed and every consecutive ten distance values were averaged to smooth the plots of all dis-
tance measurements in this study.
(TIFF)
S6 Fig. Compounds selected for in silico docking. 3D and 2D structures were downloaded
from PubChem and ChemSpider. ABCG2 substrates: Acetaminophen-sulfate (CID: 83939),
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Acyclovir (CID: 2022), Afatinib (CID: 10184653), Albendazole-sulphoxide (CID: 83969),
Arry-334543 (CID: 42642648), Benzo(a)pyrene (CID: 2336), Benzoylphenylurea (CID: 74566),
Ciprofloxacin (CID: 2764), D-Luciferin (CID: 5484207), Danusertib (CID: 11442891), Eltrom-
bopag (CID: 9846180), Flavopiridol (CID: 5287969), Icotinib (CID: 22024915), Masitinib
(CID: 10074640), Methotrexate (CID: 126941), N-Acetyl-amonafide (CID: 10064887), Pheo-
phorbide A (CID: 5323510), Protoporphyrin IX (CID: 4971), Purpurin18 (CID: 5489047),
Rhodamine123 (CID: 65218), Rosuvastatin (CID: 446157), Sulfasalazine (CID: 5359476), Tan-
dutinib (CID: 3038522), Telatinib (CID: 9808844), and Uric-Acid (CID: 1175). Non-substrates:
Calcein (CID: 65079), Calcein AM (ChemSpiderID: 346571), Colchicine (CID: 6167), Digoxin
(ChemSpiderID: 206532), Doxycycline (CID: 54671203), Fluo-3 (ChemSpiderID: 94730),
LTC4 (ChemSpiderID: 4444133), NEM-GS (CID: 443150), Ketoconazole (CID: 456201),
Loperamide (CID: 3955), Quinidine (CID: 441074), Reserpine (CID: 5770), Verapamil (CID:
2520), and Vinblastine (ChemSpiderID: 12773).
(TIF)
S7 Fig. Non-substrates are limited in accessing binding Site 2.We performed in silico dock-
ing calculations for flavopiridol and methotrexate, two established ABCG2 substrates (green
labels) as well as verapamil and calcein, which are not transported substrates of ABCG2 (red
labels), to the six equilibrated conformation of the transporter. Although we could observe
binding to Site 1 (blue) for all compounds, access of verapamil to Site 2 (red), which is the bind-
ing pocket including R482, was decreased compared to that of substrates. Calcein also exhibited
a limited access to this site, without deep penetration into it. These observations suggest that
these ABCG2 conformations can be employed in future studies for developing in silico meth-
ods to distinguish substrates and non-substrates. Moreover, Site 2 may be the gate that differ-
entiates between toxic molecules and tolerated metabolites. The black box indicates the search
space defined in all of our docking calculations. Docking to one of the six equilibrated confor-
mations is shown.
(TIFF)
S8 Fig. Quantitative analysis of sites of a potential translocationpathway. After visual
inspection of all the binding poses (20 poses x 6 protein conformations) of falvopiridol and
methotrexate, we assigned amino acids semi-manually to binding Site 1 (Q126, D127, D128,
D128, V129, V129, V130, V130, M131, M131, G132, G132, T133, T133, L134, V178, V178,
G179, G179, T180, T180, Q181, F182, F182, I183, I183, R191, R191, N387, N387, L388, G390,
N391, N391, P392, Q393, Q393, A394, A394, A397, Q398, S443, A444, E446, L447, L447, F448,
V449, V449, V450, V450, E451, K452, K453, K453, L454, I456, K473, D477), Site 2 (L388,
A394, A397, Q398, I399, V401, T402, L405, Q437, C438, S440, S441, V442, S443, A444, V445,
E446, L447, F448, V450, K473, D477, L478, M481, R482, P485, S486, A517, A520, S521,
A524), Site 3 (A397, V401, F439, F439, S440, V442, V442, S443, S443, V445, V445, E446,
E446, L447, V449, V533, V534, V534, S535, S535, V536, A537, T538, T538, L539, L540, M541,
M541, T542, I543, F545) and Site 4 (Y413, I423, Q424, Q424, N425, A427, A427, G428, G553,
G553, L554, L554, L555, L555, V556, N557, N557, F578, F586, P602, C603, N604, Y605, A606,
T607, L614, Q617, G618, I619, L621). (A) Colors red, blue, yellow, magenta, deep purple,
orange, and green label Sites 1, 2, 3, and 4, overlap of Sites 1–2, 2–3, and 1–3. Although there is
an overlap in the amino acids of sites, a docked pose can be assigned to a binding site based on
the numbers of interacting amino acids of two sites with the small molecule. The overlap of
binding sites indicates a pathway and a mechanism of transport by binding of a molecule
somewhere to the pathway followed by its moving forward to a next site closer to the extracel-
lular space. For example binding to Site 1, which seems to be the most accessible site, can be
followed by the movement to Site 2. Site 2 includes R482, which position has an effect on
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substrate specificity, and may participate in substrate selection.Non-substrates may not pene-
trate deeply into this site to induce conformational changes necessary for moving forward on
the pathway. Although the initial set of molecules (4 substrates and 2 non-substrates) provided
a hint for binding site identification, their low number may not be sufficient for representative
results. Therefore we investigated the docking of additional 21 substrates and 12 non-sub-
strates. All poses ((25+14 molecules) x 20 poses x 6 protein conformations) were automatically
assigned to binding sites. (B)Although a density plot of binding affinities indicates lower bind-
ing energies for substrates compared to non-substrates, there are also poses of non-substrates
with low binding energies, thus in silico values cannot be used to characterize the binding of
molecules. Therefore we determined the frequency of substrates and non-substrates in each
binding site. (C) The number of substrates and non-substrates bound to each binding site was
counted and normalized to the number of molecules in the two categories (substrate or not)
and to the number of poses. The values are shown in the table. Binding Site 1 was highly popu-
lated and more non-substrate poses can be found in this site as compared to substrate poses.
Althoughmany poses of non-substrate molecules can be found in Site 2, still this is the site
showing increased binding of substrates as compared to non-substrates. These results strongly
indicate a distinguished role of Site 2 in substrate selection.When generating sophisticated in
silicomethods for predicting substrates of ABCG2, this Site 2 should be considered with higher
weights in model building. Site 3, which is located in the hydrophobic transmembrane region
between the two ABCG2monomers, accommodates both substrates and non-substrates
equally well. However, it is important to note that the access to this site might be limited in
vivo (e.g. by the loop between the β1 and β2 strands of NBD), while in silico methods can place
any fitting molecule into this volume.
(TIFF)
S9 Fig. The R482Gmutation has a pronounced effect on TM helix orientation and dynam-
ics. In spite of the relatively short time periodswe can cover in MD simulations, two interesting
changes can be observed in this mutant, as compared to the wild type protein. In one of the
simulations in chain B the distance betweenR482 (TH3) and Q398 (TH1) was largely
increased in the mutant (top right panel). Moreover, in the other chain and in all of the simula-
tions, the distance betweenR482 and Q398 increased faster, as compared to the wild type (top
left panel). These observations strongly suggest that while these relative movements of TH1
and TH3 are observable in both the wild type and the mutant proteins, the interaction between
TH1 and TH3 is more dynamic in the R482G variant as compared to the wild type. In addition,
the distance betweenR482 and A517 significantly shortened in R482G (bottom panels), thus
TH3 and TH4 can get into a more intimate contact, because of the lack of a long side chain in
TH3.We could not observe significant differences in distances between TH3 and TH2 (middle
panels) caused by this mutation.
(TIFF)
S10 Fig. The CRACmutant Y413S does not affect the dynamics of TH1. In order to charac-
terize the relative orientation and movement of TH1, in which the mutated residue is located,
the interaction of amino acids located at the two ends of TH1 were measured throughout the
six trajectories for both the wild type and the Y413S mutant ABCG2.Cα distances of I399 (tur-
quoise) and P485 (red) were calculated in addition to that of Y413 (blue) and V556 (magenta).
We could observe a larger change only in one Y413S simulations, when the distance between
these two residues were altered. However, similar changes could also be observed for a WT
simulation. This most likely happens because the Leu-basedmotif resides in a loop region that
may exhibit propensity for higher dynamics.
(TIFF)
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S1 Table. The in silicomethod (HMMTOP) [56,57] predicted better location of TM helices
compared to experimentally concluded boundaries based on HA-insertion [54,55].
(TIF)
S2 Table. Vina docking scores are better (lower values) for ABCG2 transported substrates,
as compared to the values for non-substrates in most of the cases.For clarity only values for
the initial set of 4 substrates and 2 non-substrates are listed.
(TIF)
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